medline.ch Onkologie Urologische Tumoren

	To characterize small renal cell carcinoma using diffusion relaxation correlation spectroscopic imaging and apparent diffusion coefficient based histogram analysis: a preliminary study. Radiol Med Dai Y, Zhu M, Hu W, Wu D, He S, Luo Y, Wei X, Zhou Y, Wu G, Hu P. PMID: 38662246 [PubMed - as supplied by publisher]
	The survival benefit of metastasectomy for metastatic non-clear cell renal cell carcinoma: a retrospective cohort study. World J Urol Dai J, He B, Zhang Y, Zhang H, Hu X, Xu L, Ni Y, Zhang X, Sun G, Zeng H, Shen P, Liu Z. PMID: 38662226 [PubMed - indexed for MEDLINE]
	Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO GUIDELINE (2017; Amended 2020, 2024). J Urol Holzbeierlein J, Bixler BR, Buckley DI, Chang SS, Holmes RS, James AC, Kirkby E, McKiernan JM, Schuckman A. PMID: 38661067 [PubMed - as supplied by publisher]
	The efficacy and safety of stereotactic body radiotherapy combined with systematic therapy for metastatic renal cell carcinoma: a systematic review and meta-analysis. MedComm (2020) Zhang S, Xiong X, Xie N, Zheng W, Li Y, Lin T, Wei Q, Tan P. PMID: 38660686 [PubMed]
	A three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinoma. Front Immunol Betancor YZ, Ferreiro-Pantín M, Anido-Herranz U, Fuentes-Losada M, León-Mateos L, García-Acuña SM, Vaamonde-Rodríguez V, García-Pinel B, Cebey-López V, Villaverde-Viaño R, Lombardía-Rodríguez H, Kotrulev M, Fernández-Díaz N, Gomez-Tourino I, Fernández-Baltar C, García-González J, Tubio JMC, López-López R, Ruiz-Bañobre J. PMID: 38660294 [PubMed - indexed for MEDLINE]
	Perfusion drugs for nonâ€‘muscle invasive bladder cancer (Review). Oncol Lett Qian J, Zhang Q, Cao Y, Chu X, Gao Y, Xu H, Cai H, Wu J. PMID: 38659423 [PubMed]
	MOICS, a novel classier deciphering immune heterogeneity and aid precise management of clear cell renal cell carcinoma at multiomics level. Cancer Biol Ther Liu Y, Qi L, Ye B, Wang A, Lu J, Qu L, Luo P, Wang L, Jiang A. PMID: 38659199 [PubMed - indexed for MEDLINE]
	First-line immunotherapy of metastatic renal cell carcinoma: an updated network meta-analysis including triplet therapy. BJU Int Yanagisawa T, Kawada T, Bekku K, Laukhtina E, Rajwa P, von Deimling M, Chlosta M, Quhal F, Pradere B, Karakiewicz PI, Mori K, Kimura T, Shariat SF, Schmidinger M. PMID: 38659099 [PubMed - as supplied by publisher]
	Increased level of serum leucine-rich-alpha-2-glycoprotein 1 in patients with clear cell renal cell carcinoma. BMC Urol Nakanishi S, Goya M, Suda T, Yonamine T, Sugawa A, Saito S. PMID: 38658967 [PubMed - indexed for MEDLINE]
	PD-L1 expression in tumor and inflammatory cells is associated with favorable tumor features and favorable prognosis in muscle-invasive urothelial carcinoma of the bladder not treated by immune checkpoint inhibitors. BMC Urol Plage H, Furlano K, Hofbauer S, Weinberger S, Ralla B, Franz A, Fendler A, de Martino M, Roßner F, Elezkurtaj S, Kluth M, Lennartz M, Blessin NC, Marx AH, Samtleben H, Fisch M, Rink M, Slojewski M, Kaczmarek K, Ecke T, Hallmann S, Koch S, Adamini N, Zecha H, Minner S, Simon R, Sauter G, Weischenfeldt J, Klatte T, Schlomm T, Horst D, Schallenberg S. PMID: 38658905 [PubMed - indexed for MEDLINE]
	Alternative splicing in prostate cancer progression and therapeutic resistance. Oncogene Rawat C, Heemers HV. PMID: 38658776 [PubMed - as supplied by publisher]
	MMPs-related risk model identification and SAA1 promotes clear cell renal cell carcinoma migration via ERK-AP1-MMPs axis. Sci Rep Wei H, Li Y, Zhang J, Xu C, Wei D, Quan C, Zhu S. PMID: 38658579 [PubMed - indexed for MEDLINE]
	Comparison of novel PSMA-targeting [(177)Lu]Lu-P17-087 with its albumin binding derivative [(177)Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study. Eur J Nucl Med Mol Imaging Li L, Wang J, Wang G, Wang R, Jin W, Zang J, Sui H, Jia C, Jiang Y, Hong H, Zhu L, Alexoff D, Ploessl K, Kung HF, Zhu Z. PMID: 38658392 [PubMed - as supplied by publisher]
	Part I: prostate cancer detection, artificial intelligence for prostate cancer and how we measure diagnostic performance: a comprehensive review. Curr Probl Diagn Radiol Maki JH, Patel NU, Ulrich EJ, Dhaouadi J, Jones RW. PMID: 38658286 [PubMed - as supplied by publisher]
	Surveillance of non-muscle-invasive bladder cancer with blue-light cystoscopy: a meta-analysis. BJU Int Sari Motlagh R, Ghoreifi A, Yanagisawa T, Kawada T, Ahyai S, Merseburger AS, Abufaraj M, Abern M, Djaladat H, Daneshmand S, Shariat SF. PMID: 38658172 [PubMed - as supplied by publisher]
	Bisphenol S enhances the cell proliferation ability of prostate cancer cells by regulating the expression of SDS. Toxicol In Vitro Ju G, Zhan X, Chen X, Zhang T, Zhai X, Chu C, Tan M, Xu D. PMID: 38657712 [PubMed - as supplied by publisher]
	Biparametric MRI in prostate cancer during active surveillance: is it safe? Eur Radiol Caglic I, Sushentsev N, Syer T, Lee KL, Barrett T. PMID: 38656709 [PubMed - as supplied by publisher]
	Limited prognostic role of routine serum markers (AP, CEA, LDH and NSE) in oligorecurrent prostate cancer patients undergoing PSMA-radioguided surgery. World J Urol Mehring G, Steinbach C, Pose R, Knipper S, Koehler D, Werner S, Riethdorf S, von Amsberg G, Ambrosini F, Maurer T. PMID: 38656636 [PubMed - indexed for MEDLINE]
	Study on the Role and Mechanism of SLC3A2 in Tumor-Associated Macrophage Polarization and Bladder Cancer Cells Growth. Technol Cancer Res Treat Wu P, Zhao L, Kong G, Song B. PMID: 38656249 [PubMed - indexed for MEDLINE]
	Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study. Elife Bergamini M, Dalla Volta A, Palumbo C, Zamboni S, Triggiani L, Zamparini M, Laganà M, Rinaudo L, Di Meo N, Caramella I, Bresciani R, Valcamonico F, Borghetti P, Guerini A, Farina D, Antonelli A, Simeone C, Mazziotti G, Berruti A. PMID: 38656229 [PubMed - indexed for MEDLINE]

Artikel 1 - 20 / 160894

Seite 1 von 8045

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung